The promise of new antiepileptic drugs

British Journal of Clinical Pharmacology

Volumn 53, Issue 2, 2002, Pages 123-131

  Duncan, John S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CHLOROPHENYL) 4 MORPHOLINO 3 IMIDAZOLIN 2 ONE; 4 AMINOBUTYRIC ACID DERIVATIVE; AMIDE; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; CARABERSAT; CARBAMAZEPINE; ETIRACETAM; FOSPHENYTOIN SODIUM; GABAPENTIN; HARKOSERIDE; ISOVALERAMIDE; LAMOTRIGINE; LORAZEPAM; MESYLIC ACID DERIVATIVE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PROPIONAMIDE DERIVATIVE; RETIGABINE; RUFINAMIDE; SAFINAMIDE; SP 0294; TALAMPAREL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VALROCEMIDE; VIGABATRIN; ZONISAMIDE;

BRAIN INJURY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EPILEPTIC STATE; HUMAN; LONG TERM CARE; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

ANTICONVULSANTS; HUMANS; SEIZURES; STATUS EPILEPTICUS;

EID: 0036202836     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01540.x     Document Type: Review

References (89)

1. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK
2. Proposal for revised clinical and electroencephalographic classification of epileptic seizures
3. Proposal for revised classification of epilepsies and epileptic syndromes
4. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: Report of the ILAE task force on classification and terminology
5. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures
6. Some aspects of prognosis in the epilepsies: A review
7. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures
8. The impact of new antiepileptic drugs on the prognosis of epilepsy: Seizure freedom should be the ultimate goal
9. New antiepileptic drugs. A systematic review of their efficacy and tolerability
10. The new antiepileptic drugs. A systematic review of their efficacy and tolerability
11. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome
12. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome
13. Long term use oflamotrigine and vigabatrin in severe refractory epilepsy: Audit of outcome
14. A survey comparing lamotrigine and vigabatrin in everyday clinical practice
15. Topiramate in clinical practice: First year's postlicensing experience in a specialist epilepsy clinic
16. The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy
17. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy
18. Quality of life in people with epilepsy: A European study
19. Assessing the psychosocial consequences of epilepsy: A community-based study
20. The development of a seizure severity scale as an outcome measure in epilepsy
21. Quantitative approaches to seizure severity
22. The National Hospital seizure severity scale. A further development of the Chalfont seizure severity scale
23. Cognitive and behavioural assessments in clinical trials: What type of measure?
24. Convulsive status epilepticus
25. Fosphenytoin and phenytoin in patients with status epilepticus: Improved tolerability versus increased costs
26. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy
27. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
28. A randomised open multicentre comparative trial oflamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy
29. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures
30. Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study
31. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: A multicentre randomised double-blind study
32. Vigabatrin versus carbamazepine monotherapy in newly diagnosed focal epileptics: A randomized response conditional cross-over study
33. A double blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy
34. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy
35. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy
36. A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy
37. Clinical recommendations for oxcarbazepine
38. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms
39. Infantile spasms
40. Severe persistent visual field constriction associated with vigabatrin
41. Vigabatrin, a gabaergic antiepileptic drug causes concentric visual field defects
42. Adverse event monitoring in lamotrigine patients: A pharmacoepidemiologic study in the United Kingdom
43. Lamotrigine. A review of its use in childhood epilepsy
44. The tolerability of lamotrigine in children
45. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure
46. Lamotrigine elderly study group. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy
47. Vigabatrin and psychosis
48. Vigabatrin and depression
49. Gabapentin and cognition: A double-blind, dose-ranging, placebo controlled study in refractory epilepsy
50. Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults
51. Effects of topiramate on cognitive function
52. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate comapred with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures
53. Neuropsychological effects of tiagabine, a potential new antiepileptic drug
54. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy
55. Neuropsychological effects of epilepsy and antiepileptic drugs
56. Profile of anticonvulsant activity of pregabalin in animal models
57. The new anticonvulsant retigabine acts as an opener ofK + channels in neuronal cells
58. Anticonvulsant profile of CGP33101 in animal models
59. GABA and glutamate
60. Benzodiazepine actions mediated by specific gamma-aminobutyric acid (A) receptor subtypes
61. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor al subtype
62. Characterization of phenytoin-resistant kindled rats, a new model of drug-resistant partial epilepsy: Influence of genetic factors
63. MDR1 gene expression in brain of patients with medically refractory epilepsy
64. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins
65. A mouse model for valproate teratogenicity. Parental effects, homeotic transformations and altered HOX expression
66. Does antiepileptic drug therapy alter the prognosis of childhood seizures and prevent the development of chronic epilepsy?
67. Synaptic reorganization in the hippocampus induced by abnormal functional activity
68. Consequences of neonatal seizures in the rat: Morphological and behavioral effects
69. Selective changes in single cell GABA (A) receptor subunit expression and function in temporal lobe epilepsy
70. Synaptic reorganizations in human and rat hippocampal epilepsy
71. Febrile seizures in the developing brain result in persistent modification of neuronal excitability in limbic circuits
72. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy
73. Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy
74. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy
75. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse
76. Anticonvulsant and antiepileptogenic actions of MK-801 in the kindling and electroshock models
77. Pharmacological prophylaxis of post-traumatic epilepsy
78. Development of hippocampal atrophy: A serial magnetic resonance imaging study in a patient who developed epilepsy after generalized status epilepticus
79. Seizure-induced neuronal necrosis: Implications for programmed cell death mechanisms
80. Neuroprotection with felbamate: A 7- and 28-day study in transient forebrain ischemia in gerbils
81. Cerebroprotective effect of lamotrigine after focal ischemia in rats
82. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest
83. Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid: Evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy
84. Protective effect of topiramate against hippocampal neuronal damage after global ischemia in the gerbils
85. Hippocampal and cerebellar volume try in serially acquired MRI Volume scans
86. A longitudinal quantitative hippocampal MRI study in newly diagnosed localization-related epilepsies in adults: One year follow up results
87. A longitudinal quantitative MRI study of community-based patients with chronic epilepsy and newly diagnosed seizures: Methodology and preliminary findings
88. Interictal and ictal activity in the rat cobalt/pilocarpine model of epilepsy decreased by local perfusion of diazepam
89. Anticipation of epileptic seizures from standard EEG recordings